Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome

Singh, Pooja; Panda, Rajesh; Kodamanchili, Saiteja; Anand, Abhijeet

doi:10.4103/ija.ija_817_21

Cited by 2 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EULAR, in its recent update, has suggested using tofacitinib in combination with glucocorticoids as immunomodulatory therapy among critically ill or severe COVID-19 patients requiring oxygen therapy for reduced disease progression and mortality (Alunno et al, 2022). Similar findings have been reported by multiple observational studies and randomized controlled trials, suggesting the use of tofacitinib alone or in combination with dexamethasone to improve survival odds in severe and critical COVID-19 patients (Singh P. K. et al, 2021;Hayek et al, 2021;Panda et al, 2021;Shrestha et al, 2021;Ferrarini et al, 2022;Kodali et al, 2022;Murugesan et al, 2022). Based on available evidence, tofacitinib is a valid therapeutic option for COVID-19; however, more studies are needed compared to clinical trials, as the results are reported mainly from case studies.…”

Section: Jakinibs For Covid-19 Managementmentioning

confidence: 77%

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review

et al. 2023

View full text Add to dashboard Cite

Severe cases of COVID-19 are characterized by hyperinflammation induced by cytokine storm, ARDS leading to multiorgan failure and death. JAK-STAT signaling has been implicated in immunopathogenesis of COVID-19 infection under different stages such as viral entry, escaping innate immunity, replication, and subsequent inflammatory processes. Prompted by this fact and prior utilization as an immunomodulatory agent for several autoimmune, allergic, and inflammatory conditions, Jakinibs have been recognized as validated small molecules targeting the rapid release of proinflammatory cytokines, primarily IL-6, and GM-CSF. Various clinical trials are under investigation to evaluate Jakinibs as potential candidates for treating COVID-19. Till date, there is only one small molecule Jakinib known as baricitinib has received FDA-approval as a standalone immunomodulatory agent in treating critical COVID-19 patients. Though various meta-analyses have confirmed and validated the safety and efficacy of Jakinibs, further studies are required to understand the elaborated pathogenesis of COVID-19, duration of Jakinib treatment, and assess the combination therapeutic strategies. In this review, we highlighted JAK-STAT signalling in the pathogenesis of COVID-19 and clinically approved Jakinibs. Moreover, this review described substantially the promising use of Jakinibs and discussed their limitations in the context of COVID-19 therapy. Hence, this review article provides a concise, yet significant insight into the therapeutic implications of Jakinibs as potential anti-COVID agents which opens up a new horizon in the treatment of COVID-19, effectively.

show abstract

Section: Jakinibs For Covid-19 Managementmentioning

confidence: 77%

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, one patient did not respond to the treatment and finally dead on the 9 th day of ICU admission. [ 45 ]…”

Section: Safety and Efficacy Of Tofacitinib Against Coronavirus Disea...mentioning

confidence: 99%

A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019

Hashemian,

Farhadi

2023

International Journal of Critical Illness and Injury Science

View full text Add to dashboard Cite

In coronavirus disease 2019 (COVID-19), the formation of cytokine storm may have a role in worsening of the disease. By attaching the cytokines like interleukin-6 to the cytokine receptors on a cell surface, Janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathway will be activated in the cytoplasm lead to hyperinflammatory conditions and acute respiratory distress syndrome. Inhibition of JAK/STAT pathway may be useful to prevent the formation of cytokine storm. Tofacitinib is a pan inhibitor of JAKs. In this review, the main characteristics of tofacitinib and its usefulness against COVID-19 pneumonia were reviewed. Tofacitinib may be a hopeful therapeutic candidate against COVID-19 respiratory injury since it inhibits a range of inflammatory pathways. Hence, the agent may be considered a potential therapeutic against the post-COVID-19 respiratory damage. Compared to other JAK inhibitors (JAKi), the administration of tofacitinib in COVID-19 patients may be safer and more effective. Other JAKi such as baricitinib are related to severe adverse events such as thrombotic events compared to more common side effects of tofacitinib.

show abstract

Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome

Cited by 2 publications

References 8 publications

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review

Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review

A narrative review on tofacitinib: The properties, function, and usefulness to treat coronavirus disease 2019

Contact Info

Product

Resources

About